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CORRECTION
In: Acute arterial complications associated with total hip and knee arthroplasty (Calligaro KD, Dougherty
MJ, Ryan S, Booth RE. J Vasc Surg 2003;38:1170-7).
On page 1175, in the Conclusion section of this article, the acronym is incorrect. The second sentence states that
acute arterial complications were more frequent with THA [total hip arthroplasty]. The sentence should read, “In this
series these complications were more frequent with TKA [total knee arthroplasty], especially repeat knee operations.”
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